CIPH Ciphergen Biosystems (MM)

Ciphergen Names Diagnostics Division Vice President of Clinical and Medical Affairs FREMONT, Calif., July 14 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH) announced today that Dr. Eric Fung, M.D., Ph.D. has been promoted to the position of Vice President, Clinical and Medical Affairs, in its newly formed Diagnostics Division. In his new position, Dr. Fung will manage the clinical and medical research that forms the basis of a major clinical diagnostics business initiative by the company to develop and commercialize Protein Molecular Diagnostics, based on the ProteinChip(R) platform. In his new position, he will report to Gail S. Page, President of Ciphergen's Diagnostics Division. "Dr. Fung has played a key role in developing and managing our diagnostic biomarker pipeline and fostering our collaborations with key accounts such as Johns Hopkins Medical School, MD Anderson, and Eastern Virginia Medical School over the last four years," stated Gail S. Page, President of Ciphergen's Diagnostics Division. "His combination of clinical and scientific experience has been a critical factor in Ciphergen's success." Dr. Fung joined Ciphergen in 2000 as a lead scientist in the newly formed Biomarker Discovery Center(R) laboratories and managed many of Ciphergen's academic and pharmaceutical collaborations. He was most recently Director of Clinical Affairs. Prior to joining Ciphergen, Dr. Fung was a Howard Hughes sponsored researcher at Stanford University, working under Dr. Richard Scheller. Dr. Fung has anatomic pathology training from Stanford Medical School, and obtained his M.D. and Ph.D. degree in molecular neuroscience from the Johns Hopkins University School of Medicine. He graduated with a BS in biology with honors from the California Institute of Technology. Dr. Fung also currently holds an Adjunct Assistant Professor position in the Department of Pathology at the Johns Hopkins University School of Medicine. Beginning in 2000, Ciphergen established the first of a series of Biomarker Discovery Center(R) laboratories and established a major collaboration with the Johns Hopkins University School of Medicine with the intention of employing Ciphergen technology to discover biomarkers and develop assays based on multi-biomarkers which might have greater predictive power than single marker tests. While Ciphergen is perhaps best noted for its diagnostic efforts in the early detection in cancer, the company also has active discovery programs underway in neurology, cardiovascular and infectious disease, focused on a variety of clinical questions including disease detection, treatment response, monitoring, classification and prognosis. About Ciphergen Ciphergen's Biosystems Division develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research, and process proteomics applications, as well as a broad range of bioseparations media for protein purification and large scale production. ProteinChip Systems enable protein discovery, characterization, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Ciphergen's Diagnostics Division is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the use of ProteinChip technology to discover useful protein biomarkers that can act as novel drug targets or disease markers, develop and commercialize clinical diagnostics that improve patient care, the ability to provide services that lead to improved toxicology assays and diagnostic assays, and statements regarding our Diagnostics Division. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the ProteinChip technology's ability to validate and/or develop protein biomarkers as novel drug targets, diagnostic or toxicology assays, and the Company's ability to successfully commercialize such tests. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-Q dated May 10, 2004 and amended May 20, 2004, for further information regarding these and other risks of the Company's business. NOTE: Ciphergen, ProteinChip, Biomarker Discovery Center and BioSepra are registered trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: investors, Sue Carruthers of Ciphergen Biosystems, Inc., +1-510-505 2297 Web site: http://www.ciphergen.com/

Copyright